%0 Journal Article
%A Ponce Aix, Santiago
%A Talbot, Denis
%A Govindan, Ramaswamy
%A Dols, Manuel Cobo
%A Postmus, Pieter E
%A Lewanski, Conrad
%A Bennouna, Jaafar
%A Fischer, Juergen R
%A Juan-Vidal, Oscar
%A Stewart, David J
%A Ardizzoni, Andrea
%A Bhore, Rafia
%A Wolfsteiner, Marianne
%A Reck, Martin
%A Ong, Teng Jin
%A Morgensztern, Daniel
%T Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer.
%D 2020
%U http://hdl.handle.net/10668/15304
%X Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.
%K EORTC QLQ-C30
%K EQ-5D-5L
%K durvalumab
%K lung cancer symptom scale
%K nab-paclitaxel
%K non-small cell lung cancer
%K quality of life
%~